Fensiglen 5 Mg , 10 Mg 5 mg, 10 mg Fim-coated tablets
PDF Leaflet Revision Date: 17 September 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Symptomatic treatment of overactive bladder syndrome.
Dosage (summary)
5 mg once daily, may increase to 10 mg once daily.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Potent CYP3A4 inhibitors
- Anticholinergic drugs
Contraindications
- Hypersensitivity to solifenacin
- Urinary retention
- Narrow angle glaucoma
- Myasthenia gravis
- Toxic megacolon
- Severe renal impairment
- Severe hepatic impairment
Common side effects
- Dry mouth
- Constipation
- Dizziness
- Blurred vision
Counselling Points
- Take orally with or without food.
- May cause blurred vision; caution when driving.
- Report any signs of allergic reactions.
Serious warnings
- Risk of urinary retention
- QT prolongation
- Angioedema
Important Disclaimer
The Fensiglen 5 Mg , 10 Mg 5 mg, 10 mg Fim-coated tablets professional information leaflet below is the property of Glenmark Pharmaceuticals South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
